[Tempus AI, Inc.] Tempus AI, Inc., and Blood Cancer United^® announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia, a rare and aggressive blood cancer.

[Nature] Researchers showed that infection with the helminth Heligmosomoides polygyrus increases erythroid-primed multipotent progenitor commitment to myeloid fate at the expense of erythropoiesis.

[Blood] Scientists demonstrated that microRNA-126 (miR-126) maintained leukemic stem cells function by promoting B-cell lymphoma 2–dependent FAO, OXPHOS, and mitofusion, whereas its inhibition disrupts mitochondrial metabolism, induces mitochondrial fission, and triggers apoptosis.

[Cell Death & Disease] Researchers demonstrated that histone deacetylase 6 (HDAC6) loss significantly impairs myeloid leukemia progression in vivo, despite having no functional impact on leukemia cell proliferation in vitro.

[Molecular Cancer Therapeutics] Investigators evaluated the efficacy of menin inhibition in T-lineage acute lymphoblastic leukemia (T-ALL) and identified molecular predictors of sensitivity. They tested menin inhibitors, ziftomenib, revumenib, VTP-50469, in 14 primary T-ALL samples and 8 cell lines, representing HOXA-high and HOXA-low genotypes.

[Experimental Hematology] The authors demonstrated that MYC overexpression from the endogenous locus, which maintains physiological regulation, results in a transient and reversible differentiation block that is insufficient for leukemogenesis.

[Blood] This phase III trial randomized adult patients with acute leukemias or myelodysplastic syndrome undergoing myeloablative conditioning to receive either Orca-T with tacrolimus or a conventional allograft with tacrolimus and methotrexate, using granulocyte colony-stimulating factor–mobilized peripheral blood from HLA-matched donors.

[Blood Advances] Investigators analyzed a cohort of 118 adult patients with de novo AML, among whom 27 developed extramedullary disease (EMD) in various body sites, with tissue involvement as the most common.

[European Journal of Haematology] The authors summarize the evolving treatment landscape for older patients with acute lymphoblastic leukaemia, from conventional chemotherapy to novel immunotherapeutic approaches.

[Experimental Hematology] Scientists considers how inflammation triggers or amplifies the functional ramifications of conditionally pathogenic variation as a blood pathogenic mechanism, with a particular emphasis on GATA2 and RUNX1 transcription factor-linked mechanisms.

[Advanced Science] High-frequency amplification of the 17p11.2 chromosomal region in osteosarcoma represents a key molecular event driving malignant progression. Investigators focused on the key gene COPS3 in this region, delving into its molecular mechanisms regulating cancer stemness.

[Cancer Letters] Researchers demonstrated that mesenchymal glioblastoma stem cells exhibit a preferential expression and secretion of the protein LY96.